YOUR SEARCH FOR Text 261 RESULTS
131 of Total
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
View all news Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs April 29, 2025 at 7:00 AM EDT PDF
132 of Total
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
View all news Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs July 29, 2025 at 7:00 AM EDT PDF
133 of Total
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates | Incyte
View all news Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates April 28, 2026 at 7:00 AM EDT PDF Version Total
134 of Total
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results | Incyte
View all news Incyte Reports Fourth Quarter and Full Year 2025 Financial Results February 10, 2026 at 7:00 AM EST PDF Version Total revenue of $1.51
135 of Total
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Incyte
View all news Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 7, 2026 at 4:30 PM EDT PDF Version WILMINGTON, Del. --(
136 of Total
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates | Incyte
View all news Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates October 28, 2025 at 7:00 AM EDT PDF Version Total
137 of Total
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult a
View all news Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with
138 of Total
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the Europ
View all news Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate
139 of Total
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, E
140 of Total
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
A New Frontier
in Hematology
Incyte proudly adds VGA039 and the
VIVID study to its hematology portfolio.